Despite a sharp decline in healthcare M&A during 2020, the outlook for pharma and biotech remains strong. Overall healthcare deal value fell significantly during the pandemic, with pharma and biotech experiencing an even steeper drop. However, companies in these sectors are well positioned for a rebound as they increasingly use acquisitions to drive top‑line growth rather than relying solely on cost efficiencies. Revenue growth has proven to be a much larger contributor to total shareholder returns than margin expansion. At the same time, rising regulatory scrutiny across healthcare is reshaping strategies, encouraging firms to pursue targeted acquisitions that strengthen portfolios, enhance innovation pipelines, and support sustainable growth in 2021 and beyond.

Join for free to read